Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 High incidence and prevalence of autoimmune diseases
3.2.1.2 Growing awareness about autoimmune diseases
3.2.1.3 Supportive government policies for research activities on autoimmune diseases
3.2.1.4 Technological advancements and increasing adoption of lab automation technologies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Need for high capital investment in setting-up diagnosis centers
3.2.2.2 Slow turnaround time for test results and need for multiple diagnostic tests
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Reagents and consumables
5.3 Instruments
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Systemic autoimmune disease
6.2.1 Rheumatoid arthritis
6.2.2 Systemic lupus erythematosus (SLE)
6.2.3 Psoriasis
6.2.4 Multiple sclerosis
6.2.5 Other systemic autoimmune diseases
6.3 Localized autoimmune disease
6.3.1 Inflammatory bowel disease
6.3.2 Type 1 diabetes
6.3.3 Thyroid
6.3.4 Other localized autoimmune diseases
Chapter 7 Market Estimates and Forecast, By Test Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Antinuclear antibody tests
7.3 Autoantibody tests
7.4 C-reactive protein (CRP)
7.5 Complete blood count (CBC)
7.6 Urinalysis
7.7 Other tests
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Diagnostics centers
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Bio-rad Laboratories, Inc.
10.3 DIAsource ImmunoAssays SA
10.4 Euroimmun AG (Perkin Elmer)
10.5 F. Hoffmann-la Roche Ltd.
10.6 Hemagen Diagnostics
10.7 Myriad Genetics
10.8 Quest Diagnostics
10.9 Siemens Healthineers Inc.
10.10 SQI Diagnostics Inc.
10.11 Thermo Fisher Scientific Inc.
10.12 Trinity Biotech Plc.
